Theorem Clinical Research

Drug Sponsors

Shire acquires Lumena Pharmaceuticals

Monday, May 12, 2014 12:21 PM

Shire will acquire Lumena Pharmaceuticals, a biopharmaceutical company with rare disease pipeline assets, for an upfront payment of $260 million in cash, plus a payment at closing and near-term contingent milestone payments related to ongoing clinical trials.

More... »

Akorn to acquire VersaPharm for $440 million

Monday, May 12, 2014 12:17 PM

Akorn, a niche pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals, will acquire VPI Holdings, the parent company of VersaPharm, a developer and marketer of generic pharmaceuticals to niche markets within the U.S., for $440 million in cash.

More... »

Lundbeck to acquire Chelsea Therapeutics

Friday, May 9, 2014 12:25 PM

H. Lundbeck of Denmark and North Carolina-based Chelsea Therapeutics International have entered into a definitive agreement under which Lundbeck will acquire Chelsea.

More... »

Theravance to split into two companies: R&D and royalty management

Thursday, May 8, 2014 01:21 PM

Biopharmaceutical company Theravance has announced it will split into two independent, publicly traded companies via a stock dividend on May 15.

More... »

IMS Health acquires Forcea

Thursday, May 8, 2014 01:14 PM

IMS Health, a global information and technology services company, has acquired Forcea, a Belgium-based provider of business intelligence applications and analytics for hospitals and life sciences organizations.

More... »

EY report: Lack of trust keeps pharmas, payers divided on drug costs, trial data

Wednesday, May 7, 2014 02:58 PM

By Ronald Rosenberg
CenterWatch Staff Writer

The “lingering mistrust” between the pharmaceutical industry and payers over lowering drug costs and improving outcomes will make new approaches of engagement highly unlikely without a fundamental change in current approaches.

More... »

Bayer to acquire Merck’s consumer care business, partner on sGC modulators

Wednesday, May 7, 2014 01:30 PM

Bayer has agreed to acquire Merck’s consumer care business for $14.2 billion. Bayer also has entered into a global co-development and co-commercialization agreement with Merck in soluble guanylate cyclase (sGC) modulators, for which Merck will make an up-front payment to Bayer of $1 billion, with substantial additional sales milestones.

More... »

Aeterna Zentaris to house business, commercial operations in Charleston, S.C.

Wednesday, May 7, 2014 01:12 PM

Aeterna Zentaris, a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology, has selected Charleston, S.C., for its North American business and global commercial operations. Over the next five years, Aeterna Zentaris will hire staff to support commercial operations, business development, regulatory and quality assurance, manufacturing management, clinical and product development, as well as various administrative functions. The Coordinating Council for Economic Development of South Carolina has approved job development credits to Aeterna Zentaris.

More... »

Shire acquires Fibrotech for $75M

Friday, May 2, 2014 11:32 AM

Shire, a global specialty biopharmaceutical company, has acquired Fibrotech, an Australian biopharmaceutical company developing a new class of drugs associated with fibrosis, for an up-front payment of $75 million plus certain development and regulatory milestone payments.

More... »

Endo to acquire Somar

Thursday, May 1, 2014 10:29 AM

Endo International will acquire Grupo Farmaceutico Somar, a privately owned specialty pharmaceuticals company based in Mexico City, Mexico. Endo expects the transaction to be immediately accretive to adjusted earnings per share. Financial details have not been disclosed.

More... »

Subscribe to The CenterWatch Monthly



Browse by:


September 22

Roche/Genentech plans pilot trial to measure patientpreference for participating at home v. at study site

Bipartisan 21st Century Cures initiative prepares to draft legislation to accelerate biomedical R&D, lower cost

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs